About
SFA Therapeutics develops deuterated short-chain fatty acid drug candidates that aim to modulate the gut-immune axis. Its lead investigational oral candidate, SFA-002, is being developed to treat plaque psoriasis (completed an open-label Phase 1b and preparing a randomized Phase 2).
Explore SFA Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.